Physicians' Academy for Cardiovascular Education

Agenda Topics ▼On-demand Online-CME Podcasts News ▼Meeting Reports Slides ▼About

ACC.21 ▼AHA 2020 ▼Covid-19 ▼Diabetes & CVD ▼ESC 2021 ▼HF Practical Tutorials ▼Kidney disease & CVD ▼LDL-c goal attainment in high risk patients ▼

HoFH

Feb. 8, 2015

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist needs to know about GLP-1RA

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Time to previous ACS event has no effect on efficacy of colchicine

5' education - Oct. 14, 2021 - Tjerk Opstal, MD

Benefit of colchicine independent of timing of prior ACS

Literature - Sep. 27, 2021 - Opstal TSJ, et al. - JACC 2021

Combination therapy with PCSK9 mAbs in post-MI patients

10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD

Atherosclerosis

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD

Each decade earlier of starting LDL-c lowering associated with stepwise increase in lifetime CV risk reduction

News - Aug. 31, 2021

Atrial fibrillation

Association of DOACs with adverse outcomes in older patients with AF across frailty subgroups

Literature - Oct. 19, 2021 - Kim DH, et al. - Annals of Internal Medicine 2021

Under- and overdosing of DOACs still common in patients with AF

Literature - Sep. 27, 2021 - Moudallel S et al. - Br J Clin Pharmacol. 2021

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Covid-19

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD

Therapeutic-dose of heparin does not improve outcomes in critically ill COVID-19 patients

Literature - Aug. 16, 2021 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, et al. - NEJM 2021

Atypical PF4-dependent thrombosis and thrombocytopenia in some after COVID-19 vaccination

Literature - Apr. 22, 2021 - Scully M, et al. - N Engl J Med. 2021

Covid-19, ACE2, RAASi

COVID-19, ACE2 and RAAS inhibition

Online-CME - This course consists of 3 parts.

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD

CV Inflammation

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

CVRM

Stepwise approach for prevention goals in 2021 guidelines on CVD prevention

News - Aug. 30, 2021

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

The mechanism of action of bempedoic acid

Diabetes

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD

Teaming up to tackle cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

Diabetes & CVD

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD

Teaming up to tackle cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD

No interaction between SBP and effects of SGLT2i on outcomes in HFrEF

Literature - Oct. 27, 2021 - Böhm M, et al. - J Am Coll Cardiol 2021

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

Monogenic FH and clinically defined FH remain largely undertreated

Literature - Oct. 25, 2021 - Björnsson E et al. - Arterioscler Thromb Vasc Biol. 2021

Women with FH want more information on pregnancy in relation to their condition

Literature - Oct. 20, 2021 - Klevmoen M et al. - Atherosclerosis. 2021

FDA approval for PCSK9i in children with heterozygous FH of 10 years and older

News - Sep. 27, 2021

German videos

Möglichkeiten in der Lipidtherapie die unabhängig vom LDL-c das residuale Risiko reduzieren

Residuales Risiko: Die Rolle der Hypertriglyceridämie

Global Heart Failure Academy education on ReachMD

Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach

RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy is NOT the Only Option

Common misconceptions about iron deficiency in heart failure and what to do about it

GLP-1 RA & CVD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Heart Failure

No interaction between SBP and effects of SGLT2i on outcomes in HFrEF

Literature - Oct. 27, 2021 - Böhm M, et al. - J Am Coll Cardiol 2021

The clinical dilemma of RAASi therapy and hyperkalemia

10' education - Oct. 20, 2021 - Prof. Javed Butler, MD

SGLT2i reduces cardiorenal outcomes in HFrEF irrespective of baseline NT-proBNP

Literature - Oct. 18, 2021 - Januzzi JL, et al. - J Am Coll Cardiol 2021

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

Starting with quarter-dose quadruple combination pill effectively lowers BP

News - Sep. 7, 2021

Intensive BP lowering reduces CV events in older patients with hypertension

News - Aug. 30, 2021

Replacing salt with a salt substitute reduces risk of stroke

News - Aug. 29, 2021

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Kidney disease & CVD

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD

Teaming up to tackle cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD

No interaction between SBP and effects of SGLT2i on outcomes in HFrEF

Literature - Oct. 27, 2021 - Böhm M, et al. - J Am Coll Cardiol 2021

LDL-c Key Lessons

Key lessons on LDL-c and CV risk

LDL-c Key lessons

Screening for familial hypercholesterolemia after ACS pays off

LDL-c Key Lessons

LDL-c lowering treatment impacts disease progression before clinical manifestation

LDL-c Key Lessons

Lipids

E-learning Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Online-CME - This course consists of 3 parts.

E-learning Lp(a): from CV risk marker to therapeutic target

Online-CME - This course consists of 3 parts.

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD

Lp(a)

E-learning Lp(a): from CV risk marker to therapeutic target

Online-CME - This course consists of 3 parts.

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD

PCSK9

Acute arterial events reduced by PCSK9 inhibitor across all vascular territories

Literature - Oct. 14, 2021 - Oyama K, et al. - Eur Heart J 2021

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Online-CME - This course consists of 3 parts.

Continued efficacy of LDL-c lowering, even below 40 mg/dL, in high risk patients

Literature - Sep. 8, 2021 - Marston NA et al. - Circulation 2021

Pulmonary Arterial Hypertension

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

Literature - June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

SGLT2i

No interaction between SBP and effects of SGLT2i on outcomes in HFrEF

Literature - Oct. 27, 2021 - Böhm M, et al. - J Am Coll Cardiol 2021

SGLT2i reduces cardiorenal outcomes in HFrEF irrespective of baseline NT-proBNP

Literature - Oct. 18, 2021 - Januzzi JL, et al. - J Am Coll Cardiol 2021

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

siRNA therapy and LDL-C

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Online-CME - This course consists of 3 parts.

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD

NHS agreement on population health management approach using PCSK9 siRNA therapy

News - Sep. 7, 2021

Stroke

Differential associations of eGFR and UACR with CVD subtypes in patients with diabetes

News - Sep. 29, 2021

Implementation of salt substitution strategies

3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD

Switching to a salt substitute reduces risk of stroke, CV events and death

5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD

Triglycerides

E-learning Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Online-CME - This course consists of 3 parts.

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD

© 2006 - 2021 pace-cme.org - About